{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:53:40Z","timestamp":1788612820115,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022854","name":"European Cystic Fibrosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jcf.2025.08.019","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:23:04Z","timestamp":1757568184000},"page":"1098-1104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor\/tezacaftor\/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-200X","authenticated-orcid":false,"given":"Mordechai","family":"Pollak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6225-2989","authenticated-orcid":false,"given":"Simone","family":"Gambazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-2757","authenticated-orcid":false,"given":"Annalisa","family":"Orenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Prais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4635-386X","authenticated-orcid":false,"given":"Eitan","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6683-0264","authenticated-orcid":false,"given":"Meir","family":"Mei-Zahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcf.2025.08.019_bib0001","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for Cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.019_bib0002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.08.019_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2025.08.019_bib0004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.08.019_bib0005","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202411-2231OC","article-title":"Long-term safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in adults and adolescents with cystic fibrosis and at least one F508del Allele: a phase 3, open-label extension study","author":"Daines","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.08.019_bib0006","first-page":"55","article-title":"A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis","volume":"20","author":"Harun","year":"2016","journal-title":"Paediatr Respir Rev"},{"issue":"1","key":"10.1016\/j.jcf.2025.08.019_bib0007","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1183\/09031936.00166412","article-title":"Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry","volume":"43","author":"Kerem","year":"2014","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jcf.2025.08.019_bib0008","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2025.08.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjms.2024.02.001","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on Respiratory colonization in an adult Cystic Fibrosis clinic","author":"Szabo","year":"2024","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jcf.2025.08.019_bib0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jcf.2025.08.019_bib0011","article-title":"Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis","author":"Zemke","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jcf.2025.08.019_bib0012","first-page":"01248","article-title":"Respiratory infections after elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis: analysis of the European cystic fibrosis society patient registry","author":"Pollak","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2025.08.019_bib0013","unstructured":"Zolin A., Adamoli A., Bakkeheim E., van Rens J. ECFSPR annual report 2022,. 2024."},{"key":"10.1016\/j.jcf.2025.08.019_bib0014","unstructured":"www.ecfs.eu\/ecfspr."},{"issue":"1","key":"10.1016\/j.jcf.2025.08.019_bib0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"issue":"Pt 7","key":"10.1016\/j.jcf.2025.08.019_bib0016","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1099\/mic.0.074203-0","article-title":"Inhibition of co-colonizing cystic fibrosis-associated pathogens by Pseudomonas aeruginosa and Burkholderia multivorans","volume":"160","author":"Costello","year":"2014","journal-title":"Microbiol"},{"issue":"11","key":"10.1016\/j.jcf.2025.08.019_bib0017","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1128\/IAI.01876-14","article-title":"Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus","volume":"82","author":"Schwab","year":"2014","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.jcf.2025.08.019_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00354-18","article-title":"Microbial interactions in the Cystic fibrosis airway","volume":"56","author":"Granchelli","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"12","key":"10.1016\/j.jcf.2025.08.019_bib0019","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1089\/jwh.2014.4985","article-title":"Gender differences in outcomes of patients with cystic Fibrosis","volume":"23","author":"Harness-Brumley","year":"2014","journal-title":"J Women 19s Health"},{"issue":"1","key":"10.1016\/j.jcf.2025.08.019_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2023.05.009","article-title":"Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Wang","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.019_bib0021","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ppul.22967","article-title":"The cystic fibrosis gender gap: potential roles of estrogen: cystic fibrosis gender gap and estrogen","volume":"49","author":"Sweezey","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.08.019_bib0022","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.steroids.2013.11.023","article-title":"Estrogen and the cystic fibrosis gender gap","volume":"81","author":"Saint-Criq","year":"2014","journal-title":"Steroids"},{"issue":"3","key":"10.1016\/j.jcf.2025.08.019_bib0023","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1093\/infdis\/jiae051","article-title":"Impact of CFTR modulation on Pseudomonas aeruginosa infection in people with cystic fibrosis","volume":"230","author":"Ledger","year":"2024","journal-title":"J Infect Dis"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:35:50Z","timestamp":1779953750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325015796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1569199325015796"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.08.019","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor\/tezacaftor\/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}